(PDF) Phase 2a Trial of 0, 1, and 3 Month and 0, 7, and 28

Phase 2a Trial of 0, 1, and 3 Month and 0, 7, and 28 Day Immunization Schedules of Malaria Vaccine RTS,S/AS02 in Malaria-Naïve Adults at the Walter Reed Army Institute of Research

Vaccine - Netherlands

doi 10.1016/j.vaccine.2008.02.048

Related search

Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants

New England Journal of Medicine

Medicine

2008

English

Assessment of Severe Malaria in a Multicenter, Phase III, RTS, S/As01 Malaria Candidate Vaccine Trial: Case Definition, Standardization of Data Collection and Patient Care

English

Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area

PLoS ONE

Multidisciplinary

2009

English

A Combined Analysis of Immunogenicity, Antibody Kinetics and Vaccine Efficacy From Phase 2 Trials of the RTS,S Malaria Vaccine

BMC Medicine

Medicine

2014

English

Statistical Methodology for the Evaluation of Vaccine Efficacy in a Phase III Multi-Centre Trial of the RTS,S/AS01 Malaria Vaccine in African Children

English

The RTS,S/AS01 Malaria Vaccine in Children 5 to 17 Months of Age at First Vaccination

Expert Review of Vaccines

English

Pooled Analysis of Safety Data From Pediatric Phase II RTS,S/AS Malaria Candidate Vaccine Trials

Human Vaccines

2011

English

Efficacy and Safety of RTS,S/AS01 Malaria Vaccine With or Without a Booster Dose in Infants and Children in Africa: Final Results of a Phase 3, Individually Randomised, Controlled Trial

The Lancet

Medicine

2015

English

Policy Analysis for Deciding on a Malaria Vaccine RTS,S in Tanzania

English

Amanote Research

Phase 2a Trial of 0, 1, and 3 Month and 0, 7, and 28 Day Immunization Schedules of Malaria Vaccine RTS,S/AS02 in Malaria-Naïve Adults at the Walter Reed Army Institute of Research

Vaccine - Netherlands

doi 10.1016/j.vaccine.2008.02.048

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants

Assessment of Severe Malaria in a Multicenter, Phase III, RTS, S/As01 Malaria Candidate Vaccine Trial: Case Definition, Standardization of Data Collection and Patient Care

Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area

A Combined Analysis of Immunogenicity, Antibody Kinetics and Vaccine Efficacy From Phase 2 Trials of the RTS,S Malaria Vaccine

Statistical Methodology for the Evaluation of Vaccine Efficacy in a Phase III Multi-Centre Trial of the RTS,S/AS01 Malaria Vaccine in African Children

The RTS,S/AS01 Malaria Vaccine in Children 5 to 17 Months of Age at First Vaccination

Pooled Analysis of Safety Data From Pediatric Phase II RTS,S/AS Malaria Candidate Vaccine Trials

Efficacy and Safety of RTS,S/AS01 Malaria Vaccine With or Without a Booster Dose in Infants and Children in Africa: Final Results of a Phase 3, Individually Randomised, Controlled Trial

Policy Analysis for Deciding on a Malaria Vaccine RTS,S in Tanzania